Okuzawa made president, COO of Daiichi
Plus: new commercial head at Karuna, and updates from Casma, CBER, Optinose, Rally Bio and more
Daiichi Sankyo Co. Ltd. (Tokyo:4568) named Director, Senior Executive Officer, Head of Corporate Planning & Management Division and CFO Hiroyuki Okuzawa as president and COO, effective April 1. Okuzawa has held roles of increasing responsibilities since he joined the company in 1986. President & CEO Sunao Manabe will become executive chairperson & CEO. Daiichi characterized the change as an enhancement to its management structure in response to the commercial success of Enhertu fam-trastuzumab deruxtecan-nxki and promising clinical data for the company’s other antibody-drug conjugates.
Psychiatric and neurological disease company Karuna Therapeutics Inc. (NASDAQ:KRTX) hired Will Kane as chief commercial officer, effective Feb. 6. Kane was most recently EVP, CCO at BioXcel Therapeutics Inc. (NASDAQ:BTAI) and is an 18-year veteran of Pfizer Inc. (NYSE:PFE). ...